+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year

IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.

  • Operating surplus of 255 K€ in the second half of 2019, -70 K€ over the entire year
  • Sustained increase in activity during 2019: +20%

- Initiation of SeqOIA sequencing platform operations

- Increase in activities carried out at the Institut Pasteur

  • Acceleration of software sales activities focusing on the interpretation of genomic data
  • Implementation of measures to ensure continuity of operations despite the COVID-19 pandemic with maintenance of genomic activity and preservation of financial resources

Click here to view press release

Attachments

  • Original document
  • Permalink

Disclaimer

IntegraGen SA published this content on 03 April 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 April 2020 05:37:00 UTC